Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 14,762 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De sold 14,762 shares of the stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $9.53, for a total transaction of $140,681.86. Following the completion of the sale, the chief executive officer directly owned 1,020,704 shares in the company, valued at approximately $9,727,309.12. This represents a 1.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Backer Marianne De also recently made the following trade(s):

• On Monday, February 23rd, Backer Marianne De sold 19,039 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.45, for a total transaction of $141,840.55.

Vir Biotechnology Price Performance

NASDAQ:VIR opened at $9.29 on Friday. The firm has a market capitalization of $1.30 billion, a PE ratio of -2.96 and a beta of 1.69. The business’s fifty day moving average price is $6.95 and its 200 day moving average price is $6.04. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. The company had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.Vir Biotechnology’s revenue for the quarter was up 417.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.76) EPS. As a group, equities analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Leerink Partners reiterated an “outperform” rating and issued a $20.00 price target on shares of Vir Biotechnology in a research note on Thursday. Barclays increased their target price on shares of Vir Biotechnology from $26.00 to $30.00 and gave the company an “overweight” rating in a research report on Tuesday. Needham & Company LLC lifted their price target on shares of Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday. Evercore restated an “outperform” rating and issued a $18.00 price objective on shares of Vir Biotechnology in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.89.

Trending Headlines about Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration with Vir on the prostate‑cancer asset (VIR‑5500) includes up‑front/near‑term payments and up to about $1.7 billion in contingent milestones — a material de‑risking and commercialization path for a late‑stage asset. Read More.
• Positive Sentiment: Quarterly results beat expectations: Q4 revenue (~$64M) and EPS topped consensus, signaling improving commercial traction and supporting higher analyst enthusiasm. Read More.
• Positive Sentiment: Analyst upgrades and target increases followed the news (Needham raised its target to $18), boosting upside sentiment despite current volatility. Read More.
• Neutral Sentiment: Management will present at investor conferences in early March (TD Cowen, Leerink), which can provide clarity but are not a fundamental catalyst by themselves. Read More.
• Neutral Sentiment: Comparative coverage and peer analyses are increasing visibility and trading volume (e.g., head‑to‑head pieces with peers), but they don’t change Vir’s underlying cash flow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross proceeds). The discounted placement strengthens the balance sheet but is dilutive and increases near‑term share supply, pressuring the stock. Read More.
• Negative Sentiment: Coverage noted the discounted offering as the proximate cause of the post‑rally pullback/tumble, amplifying short‑term selling. Read More.
• Negative Sentiment: Significant insider selling was disclosed (multiple officers and a director reported sales last week), which—combined with the offering—added visible supply and negative sentiment. Read More.

Institutional Investors Weigh In On Vir Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Corient Private Wealth LLC grew its holdings in shares of Vir Biotechnology by 1.0% during the fourth quarter. Corient Private Wealth LLC now owns 262,211 shares of the company’s stock worth $1,572,000 after buying an additional 2,515 shares during the last quarter. Virtus Investment Advisers LLC lifted its position in Vir Biotechnology by 82.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 39,764 shares of the company’s stock worth $240,000 after acquiring an additional 17,966 shares during the period. Tudor Investment Corp ET AL acquired a new stake in Vir Biotechnology during the 4th quarter worth approximately $414,000. Polymer Capital Management US LLC purchased a new position in shares of Vir Biotechnology in the 4th quarter valued at approximately $202,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Vir Biotechnology in the fourth quarter valued at approximately $300,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.